Suresh Siddhanti
Overview
Explore the profile of Suresh Siddhanti including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
1705
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Judge D, Alexander K, Cappelli F, Fontana M, Garcia-Pavia P, Gibbs S, et al.
J Am Coll Cardiol
. 2025 Mar;
85(10):1003-1014.
PMID: 40074465
Background: Transthyretin amyloid cardiomyopathy (ATTR-CM) is an underdiagnosed chronic disease associated with progressive heart failure that results in impaired quality of life, repeated hospitalizations, and premature death. Acoramidis is a...
2.
Soman P, Khouri M, Lenihan D, Reyentovich A, Sperry B, Sowalsky K, et al.
Future Cardiol
. 2025 Jan;
21(2):75-81.
PMID: 39878480
Introduction: The 6-minute walk test (6MWT) is used to assess submaximal exercise capacity in clinical trials. Conducting the 6MWT can be challenging when patients cannot visit the clinic due to...
3.
Razvi Y, Judge D, Martinez-Naharro A, Ioannou A, Venneri L, Patel R, et al.
Circ Heart Fail
. 2024 Oct;
17(12):e012135.
PMID: 39465243
No abstract available.
4.
Henningfield J, Gudin J, Rauck R, Gimbel J, Tagliaferri M, Doberstein S, et al.
Pain Med
. 2020 Mar;
21(8):1553-1561.
PMID: 32150255
Objective: To evaluate the SUMMIT-07 trial opioid withdrawal results of NKTR-181 (oxycodegol), a new molecular entity mu-opioid receptor agonist. Design: Phase 3, enriched-enrollment, double-blind, randomized-withdrawal study in patients with chronic...
5.
Ge X, Henningfield J, Siddhanti S, Jobes J, Lu L, Xie S, et al.
Pain Med
. 2019 Sep;
21(2):e114-e126.
PMID: 31553457
Objective: To evaluate the human abuse potential, pharmacokinetics, pharmacodynamics, and safety of oral NKTR-181 (oxycodegol), a novel full mu-opioid receptor agonist, relative to oral oxycodone. Design: This double-blind, randomized, single-dose,...
6.
Gudin J, Rauck R, Argoff C, Agaiby E, Gimbel J, Katz N, et al.
Pain Med
. 2019 Jul;
21(7):1347-1356.
PMID: 31361019
Objective: To evaluate the long-term safety of NKTR-181, a novel mu-opioid receptor agonist that may have reduced human abuse potential, in patients with moderate to severe chronic low back pain...
7.
Lanier R, Henningfield J, Gudin J, Rauck R, Elder H, Erpelding N, et al.
Curr Med Res Opin
. 2019 Apr;
35(9):1513-1522.
PMID: 30932719
To prospectively evaluate the abuse potential of NKTR-181, a novel opioid analgesic, in two phase 3 clinical trials using a newly developed reporting system: the Misuse, Abuse, and Diversion Drug...
8.
Markman J, Gudin J, Rauck R, Argoff C, Rowbotham M, Agaiby E, et al.
Pain
. 2019 Feb;
160(6):1374-1382.
PMID: 30747908
NKTR-181, a new molecular entity, mu-opioid receptor agonist with an inherently slow rate of central nervous system (CNS) entry, was designed to provide analgesia while reducing abuse potential. This phase...
9.
Webster L, Henningfield J, Buchhalter A, Siddhanti S, Lu L, Odinecs A, et al.
Pain Med
. 2017 Mar;
19(2):307-318.
PMID: 28340145
Objective: Evaluate the human abuse potential, pharmacokinetics, pharmacodynamics, and safety of NKTR-181, a novel mu-opioid agonist molecule, relative to oxycodone. Design: This randomized, single-center, double-blind, active- and placebo-controlled five-period crossover...
10.
Langdahl B, Teglbjaerg C, Ho P, Chapurlat R, Czerwinski E, Kendler D, et al.
J Clin Endocrinol Metab
. 2015 Jan;
100(4):1335-42.
PMID: 25607608
Context: One in 4 men in the United States aged >50 years will have an osteoporosis-related fracture. Fewer data are available on osteoporosis treatment in men than in women. Objective:...